September 8, 2025

Avidity Biosciences, Inc. (RNA): Analyst Consensus and Growth Potential with a 33% Upside

Avidity Biosciences, Inc. (NASDAQ: RNA) stands out in the biotechnology sector with a promising outlook for investors. As a pioneering player in the field of RNA therapeutics, the company is..

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Promising 69.99% Potential Upside in the Biotech Sector

Soleno Therapeutics, Inc. (NASDAQ: SLNO) has caught the attention of investors with its compelling potential upside of 69.99%. As a clinical-stage biopharmaceutical company, Soleno is making strides in the healthcare..

Blueprint Medicines Corporation (BPMC) Stock Analysis: Navigating a Promising Yet Volatile Biotech Landscape

Blueprint Medicines Corporation (NASDAQ: BPMC) operates within the dynamic biotechnology sector, with a focus on precision therapies targeting genomically defined cancers and blood disorders. Headquartered in Cambridge, Massachusetts, the company..

Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Is the Biotech’s Impressive 40.8% Revenue Growth a Game Changer?

Halozyme Therapeutics, Inc. (NASDAQ: HALO) is attracting substantial attention in the biotechnology sector, riding high on a robust revenue growth of 40.8%. This San Diego-based biopharmaceutical company specializes in developing..

TransMedics Group, Inc. (TMDX) Stock Analysis: Exploring a 33% Potential Upside in the Medical Devices Sector

TransMedics Group, Inc. (NASDAQ: TMDX) is capturing the attention of investors with its innovative approach to organ transplant therapy, poised for significant growth in the burgeoning healthcare sector. With a..

Exelixis, Inc. (EXEL) Stock Analysis: A 16.3% Potential Upside in Oncology Biotech

Exelixis, Inc. (NASDAQ: EXEL), a prominent player in the biotechnology sector, has made a name for itself with its focus on developing groundbreaking treatments for challenging cancers. With a market..

Axsome Therapeutics (AXSM) Stock Analysis: A Promising 41% Upside in the Booming CNS Market

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a frontrunner in the development of novel therapies for central nervous system (CNS) disorders, is capturing investor attention with a compelling potential upside of 41.28%...

AptarGroup, Inc. (ATR) Stock Analysis: Unveiling a 28.72% Potential Upside for Investors

AptarGroup, Inc. (NYSE: ATR), a prominent player in the healthcare sector under the medical instruments and supplies industry, commands significant attention with its $9.13 billion market capitalization. Headquartered in Crystal..

Nuvalent, Inc. (NUVL) Stock Analysis: A Biotech Gem with a 45% Upside Potential

Nuvalent, Inc. (NASDAQ: NUVL), a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, has captured the attention of investors with its promising pipeline of cancer therapies. Specializing in the development of..

BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Unpacking a 69% Potential Upside

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stands out in the biotechnology industry with a notable potential upside of 69.64%, according to the latest analyst ratings. This figure is particularly enticing for..

Medpace Holdings, Inc. (MEDP) Stock Analysis: Navigating a 52-Week High with Strategic Insights

Medpace Holdings, Inc. (NASDAQ: MEDP) is currently catching the eye of investors, as its stock price has reached the upper limit of its 52-week range, peaking at $486.98. As a..

RadNet, Inc. (RDNT) Stock Analysis: A Healthcare Growth Story with 8.43% Potential Upside

RadNet, Inc. (NASDAQ: RDNT), a leader in the healthcare sector, specifically within diagnostics and research, provides a compelling investment opportunity characterized by a robust growth narrative and considerable potential upside...

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Assessing the 11.25% Upside Potential

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has garnered significant attention in the biotechnology sector, particularly due to its innovative RNA-targeted medicine portfolio. With a market capitalization of $9.76 billion, Ionis is..

Legend Biotech (LEGN): Investor Outlook on a Promising Biotech with Over 114% Upside Potential

Legend Biotech Corporation (NASDAQ: LEGN) stands out as a compelling investment opportunity within the biotechnology sector. With a market capitalization of $6.66 billion, this healthcare company is making significant strides..

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Unveiling Potential Amidst Volatility and Strong Revenue Growth

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) continues to capture investor attention with its dynamic position in the biotechnology sector, particularly in the development of RNA-targeted therapeutics and gene therapies for rare..

The Ensign Group, Inc. (ENSG) Stock Analysis: Promising Growth in Healthcare Sector with Strong Buy Ratings

The Ensign Group, Inc. (NASDAQ: ENSG) is making remarkable strides in the healthcare sector, capturing the attention of investors with its robust financial performance and strategic growth in the medical..

Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Exploring a 12.10% Potential Upside for Investors

Bio-Rad Laboratories, Inc. (NYSE: BIO), a notable player in the healthcare sector, specifically in the medical devices industry, presents a compelling investment narrative for those looking to capitalize on its..

Mettler-Toledo International (MTD) Stock Analysis: Evaluating Its 0.86% Potential Downside Amidst Strong Sector Presence

Mettler-Toledo International Inc. (NYSE: MTD) stands as a prominent player in the Healthcare sector’s Diagnostics & Research industry, with a market capitalization of $26.9 billion. Headquartered in Columbus, Ohio, this..

Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring a Potential 72.85% Upside Amidst Strong Buy Ratings

Akero Therapeutics, Inc. (NASDAQ: AKRO) is capturing the attention of investors with its promising strides in the biotechnology sector, particularly in the treatment of metabolic diseases. As a company focused..

Telix Pharmaceuticals Limited (TLX) Stock Analysis: Unveiling a 154.58% Potential Upside for Biotech Investors

Telix Pharmaceuticals Limited (ASX: TLX) is making waves in the biotechnology sector with its promising portfolio of therapeutic and diagnostic radiopharmaceuticals. Operating out of Australia, this commercial-stage biopharmaceutical company has..

Search

Funds

September 8, 2025

Search

Funds

September 8, 2025

FTSE 100

Funds